{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T11:56:43Z","timestamp":1793620603765,"version":"4.5.0"},"reference-count":102,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,3,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Aspirin is effective in the prevention of cardiovascular events in high-risk patients. The primary established effect of aspirin on hemostasis is to impair platelet aggregation via inhibition of platelet thromboxane A2 synthesis, thus reducing thrombus formation on the surface of the damaged arterial wall. Growing evidence also indicates that aspirin exerts additional antithrombotic effects, which appear to some extent unrelated to platelet thromboxane A2 production. Aspirin can reduce thrombin generation with the subsequent attenuation of thrombin-mediated coagulant reactions such as factor XIII activation. Aspirin also acetylates lysine residues in fibrinogen resulting in increased fibrin clot permeability and enhanced clot lysis as well as directly promoting fibrinolysis with high-dose aspirin. The variable effectiveness of aspirin in terms of clinical outcomes and laboratory findings, which has been termed aspirin resistance, may be related to these additional antithrombotic effects that are altered when associated with common genetic polymorphisms such as the Leu33Pro \u03b23-integrin or Val34Leu factor XIII mutations. However, the clinical relevance of these observations is still unclear. Elucidation of the actual impacts of aspirin other than antiaggregation effects could be important in view of the widespread use of this drug in the prevention of thrombotic manifestations of atherosclerosis.<\/jats:p>","DOI":"10.1182\/blood-2006-01-010645","type":"journal-article","created":{"date-parts":[[2006,12,6]],"date-time":"2006-12-06T06:04:06Z","timestamp":1165385046000},"page":"2285-2292","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":209,"title":["Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions"],"prefix":"10.1182","volume":"109","author":[{"given":"Anetta","family":"Undas","sequence":"first","affiliation":[{"name":"Institute of Cardiology, Jagiellonian University School of Medicine, Krakow, Poland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen E.","family":"Brummel-Ziedins","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, University of Vermont, Colchester, VT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth G.","family":"Mann","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, University of Vermont, Colchester, VT"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2006,12,5]]},"reference":[{"key":"2019111712043741000_B1","doi-asserted-by":"crossref","unstructured":"Weiss HJ. Discovery of the antiplatelet effect of aspirin: a personal reminiscence. J Thromb Haemost2003; 1:1869\u20131875.","DOI":"10.1046\/j.1538-7836.2003.00433.x"},{"key":"2019111712043741000_B2","doi-asserted-by":"crossref","unstructured":"Awtry E and Loscalzo J. Aspirin. Circulation2000; 101:1206\u20131218.","DOI":"10.1161\/01.CIR.101.10.1206"},{"key":"2019111712043741000_B3","doi-asserted-by":"crossref","unstructured":"Antithrombotic Trialists Collaboration Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ2002; 324:71\u201386.","DOI":"10.1136\/bmj.324.7329.71"},{"key":"2019111712043741000_B4","doi-asserted-by":"crossref","unstructured":"O'Neill G and Ford-Hutchinson AW. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett1993; 330:156\u2013160.","DOI":"10.1016\/0014-5793(93)80263-T"},{"key":"2019111712043741000_B5","doi-asserted-by":"crossref","unstructured":"McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald G. Systemic biosynthesis of prostacyclin by cyclooxygenase-2. The human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A1999; 96:272\u2013277.","DOI":"10.1073\/pnas.96.1.272"},{"key":"2019111712043741000_B6","doi-asserted-by":"crossref","unstructured":"Schonbeck U, Sukhova GK, Graber P, Coulter S, Libby P. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol1999; 155:1281\u20131291.","DOI":"10.1016\/S0002-9440(10)65230-3"},{"key":"2019111712043741000_B7","doi-asserted-by":"crossref","unstructured":"Weber AA, Zimmermann KC, Meyer-Kirchrath J, Schror K. Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance. Lancet1999; 353:900.","DOI":"10.1016\/S0140-6736(99)00498-5"},{"key":"2019111712043741000_B8","doi-asserted-by":"crossref","unstructured":"Shimokawa T and Smith WL. Prostaglandin endoperoxide synthase: the aspirin acetylation region. J Biol Chem1992; 267:12387\u201312392.","DOI":"10.1016\/S0021-9258(19)49852-9"},{"key":"2019111712043741000_B9","unstructured":"Frishman WH, Lerner RG, Klein MD, Roganovic M. Antiplatelet and antithrombotic drugs. In Frishman WH, Sonnenblick EH, Sica DA (Eds.). Cardiovascular Pharmaceutics2003;New York, NY McGraw Hill pp. 259\u2013299."},{"key":"2019111712043741000_B10","doi-asserted-by":"crossref","unstructured":"Loll PJ, Picot D, Garavito RM. The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nat Struct Biol1995; 2:637\u2013643.","DOI":"10.1038\/nsb0895-637"},{"key":"2019111712043741000_B11","doi-asserted-by":"crossref","unstructured":"Moncada S and Vane JR. Arachidonic acid metabolites and the interactions between platelets and blood vessel wall. N Engl J Med1979; 300:1142\u20131147.","DOI":"10.1056\/NEJM197905173002006"},{"key":"2019111712043741000_B12","doi-asserted-by":"crossref","unstructured":"Reilly IA and Fitzgerald GA. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood1987; 69:180\u2013186.","DOI":"10.1182\/blood.V69.1.180.bloodjournal691180"},{"key":"2019111712043741000_B13","doi-asserted-by":"crossref","unstructured":"Valles J, Santos T, Aznar J, et al. Platelet-erythrocyte interactions enhance \u03b1IIb\u03b23 integrin receptor activation and P-selectin expression during platelet recruitment: down-regulation by aspirin ex vivo. Blood2002; 99:3978\u20133984.","DOI":"10.1182\/blood.V99.11.3978"},{"key":"2019111712043741000_B14","doi-asserted-by":"crossref","unstructured":"Bossavy J-P, Thalamas C, Sagnard L, et al. A double-blind randomized comparison of combined aspirin and ticlopidine therapy versus aspirin or ticlopidine alone on experimental arterial thrombogenesis in humans. Blood1998; 92:1518\u20131525.","DOI":"10.1182\/blood.V92.5.1518"},{"key":"2019111712043741000_B15","doi-asserted-by":"crossref","unstructured":"Jaffe EA and Weksler BB. Recovery of endothelial cell prostacyclin production after inhibition by low doses of aspirin. J Clin Invest1979; 63:532\u2013535.","DOI":"10.1172\/JCI109332"},{"key":"2019111712043741000_B16","doi-asserted-by":"crossref","unstructured":"Pedersen AK and FitzGerald GA. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N Engl J Med1984; 311:1206\u20131211.","DOI":"10.1056\/NEJM198411083111902"},{"key":"2019111712043741000_B17","doi-asserted-by":"crossref","unstructured":"Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-1 inhibition: therapeutic challenges and opportunities. J Clin Invest2006; 116:4\u201315.","DOI":"10.1172\/JCI27291"},{"key":"2019111712043741000_B18","doi-asserted-by":"crossref","unstructured":"Kharbanda RK, Walton B, Allen M, et al. Prevention of inflammation-mediated endothelial dysfunction: a novel vasculoprotective action of aspirin. Circulation2002; 5:2600\u20132604.","DOI":"10.1161\/01.CIR.0000017863.52347.6C"},{"key":"2019111712043741000_B19","doi-asserted-by":"crossref","unstructured":"Damas JK, Waehre T, Yndestad A, et al. Interleukin-7-mediated inflammation in unstable angina: possible role of chemokines and platelets. Circulation2003; 107:2670\u20132676.","DOI":"10.1161\/01.CIR.0000070542.18001.87"},{"key":"2019111712043741000_B20","doi-asserted-by":"crossref","unstructured":"Maree AO and Fitzgerald G. Aspirin and coronary artery disease. Thromb Haemost2004; 92:1175\u20131181.","DOI":"10.1160\/TH04-02-0127"},{"key":"2019111712043741000_B21","doi-asserted-by":"crossref","unstructured":"Demers LM, Budin RE, Shaikh BS. The effects of aspirin on megakaryocyte prostaglandin production. Proc Soc Exp Biol Med1980; 163:24\u201329.","DOI":"10.3181\/00379727-163-40716"},{"key":"2019111712043741000_B22","doi-asserted-by":"crossref","unstructured":"Eikelboom JW, Hirsh J, Weitz J.I. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation2002; 105:1650\u20131655.","DOI":"10.1161\/01.CIR.0000013777.21160.07"},{"key":"2019111712043741000_B23","doi-asserted-by":"crossref","unstructured":"Mann KG. Biochemistry and physiology of blood coagulation. Thromb Haemost1999; 82:165\u2013174.","DOI":"10.1055\/s-0037-1615780"},{"key":"2019111712043741000_B24","doi-asserted-by":"crossref","unstructured":"Kyrle PA, Westwick J, Scully MF, Kakkar VV, Levis GP. Investigation of the interaction of blood platelets with the coagulation system at the site of plug formation ex vivo in man: effect of low-dose aspirin. Thromb Haemost1987; 57:62\u201369.","DOI":"10.1055\/s-0038-1651063"},{"key":"2019111712043741000_B25","doi-asserted-by":"crossref","unstructured":"Szczeklik A, Musial J, Undas A, et al. Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia. J Am Coll Cardiol1999; 33:1286\u20131293.","DOI":"10.1016\/S0735-1097(99)00023-6"},{"key":"2019111712043741000_B26","doi-asserted-by":"crossref","unstructured":"Hampton KK, Cerletti C, Loizou LA, et al. Coagulation, fibrinolytic and platelet function in patients in long-term therapy with 300 mg or 1200 mg daily compared with placebo. Thromb Haemost1990; 64:17\u201324.","DOI":"10.1055\/s-0038-1647146"},{"key":"2019111712043741000_B27","doi-asserted-by":"crossref","unstructured":"Weiss JH and Lages B. Evidence for tissue factor-dependent activation of the classic extrinsic coagulation mechanism in blood obtained from bleeding-time wounds. Blood1989; 71:629\u2013635.","DOI":"10.1182\/blood.V71.3.629.629"},{"key":"2019111712043741000_B28","doi-asserted-by":"crossref","unstructured":"Abrams CS, Ellison N, Budzynski AZ, Shattill SJ. Direct detection of activated platelets and platelet-derived microparticles in humans. Blood1990; 75:128\u2013138.","DOI":"10.1182\/blood.V75.1.128.bloodjournal751128"},{"key":"2019111712043741000_B29","unstructured":"Undas A, Undas R, Musial J, Szczeklik A. A low dose of aspirin (75 mg\/day) lowers thrombin generation to a similar extent as a high dose of aspirin (300 mg\/day). Blood Coagul Fibrinolysis2000; 11:231\u2013234."},{"key":"2019111712043741000_B30","doi-asserted-by":"crossref","unstructured":"Undas A, Brummel K, Musial J, Mann KG, Szczeklik A. Blood coagulation at the site of microvascular injury: effects of low-dose aspirin. Blood2001; 98:2423\u20132431.","DOI":"10.1182\/blood.V98.8.2423"},{"key":"2019111712043741000_B31","doi-asserted-by":"crossref","unstructured":"Szczeklik A, Krzanowski M, Gora P, Radwan J. Antiplatelet drugs and generation of thrombin in clotting blood. Blood1992; 80:2006\u20132011.","DOI":"10.1182\/blood.V80.8.2006.bloodjournal8082006"},{"key":"2019111712043741000_B32","doi-asserted-by":"crossref","unstructured":"Musial J, Undas A, Undas R, Brozek J, Szczeklik A. Treatment with simvastatin and low-dose aspirin depresses thrombin generation in patients with coronary heart disease and borderline-high cholesterol levels. Thromb Haemost2001; 85:221\u2013225.","DOI":"10.1055\/s-0037-1615701"},{"key":"2019111712043741000_B33","doi-asserted-by":"crossref","unstructured":"Undas A, Sydor WJ, Brummel K, Musial J, Mann KG, Szczeklik A. Aspirin alters the cardioprotective effects of the factor XIII Val34Leu polymorphism. Circulation2003; 107:17\u201320.","DOI":"10.1161\/01.CIR.0000047062.03282.A3"},{"key":"2019111712043741000_B34","doi-asserted-by":"crossref","unstructured":"Undas A, Brummel K, Musial J, Mann KG, Szczeklik A. PlA2 polymorphism of \u03b23 integrins is associated with enhanced thrombin generation and impaired antithrombotic action of aspirin at the site of microvascular injury. Circulation2001; 104:2666\u20132672.","DOI":"10.1161\/hc4701.099787"},{"key":"2019111712043741000_B35","doi-asserted-by":"crossref","unstructured":"Kessels H, Beguin S, Andree H, Hemker HC. Measurement of thrombin generation in whole blood\u2014the effect of heparin and aspirin. Thromb Haemost1994; 72:78\u201383.","DOI":"10.1055\/s-0038-1648815"},{"key":"2019111712043741000_B36","doi-asserted-by":"crossref","unstructured":"Wallen NH and Ladjevardi M. Influence of low- and high-dose aspirin treatment on thrombin generation in whole blood. Thromb Res1998; 92:189\u2013194.","DOI":"10.1016\/S0049-3848(98)00126-1"},{"key":"2019111712043741000_B37","doi-asserted-by":"crossref","unstructured":"Hemker HC, Giesen P, Al Dieri R, et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb2003; 33:4\u201315.","DOI":"10.1159\/000071636"},{"key":"2019111712043741000_B38","doi-asserted-by":"crossref","unstructured":"Ratnatunga CP, Edmondson SF, Rees GM, Kovacs IB. High-dose aspirin inhibits shear-induced platelet reaction involving thrombin generation. Circulation1992; 85:1077\u20131082.","DOI":"10.1161\/01.CIR.85.3.1077"},{"key":"2019111712043741000_B39","doi-asserted-by":"crossref","unstructured":"Butenas S, Cawthern KM, van't Veer C, DiLorenzo ME, Lock JB, Mann KG. Antiplatelet agents in tissue factor-induced blood coagulation. Blood2000; 97:2314\u20132322.","DOI":"10.1182\/blood.V97.8.2314"},{"key":"2019111712043741000_B40","doi-asserted-by":"crossref","unstructured":"Butenas S, van't Veer C, Mann KG. Evaluation of the initial phase of blood coagulation using ultrasensitive assays for serine protease. J Biol Chem1997; 272:21527\u201321533.","DOI":"10.1074\/jbc.272.34.21527"},{"key":"2019111712043741000_B41","doi-asserted-by":"crossref","unstructured":"Osnes LTN, Foss KB, Joo GB, et al. Acetylsalicylic acid and sodium salicylate inhibit LPS-induced NF-kB\/c-Rel nuclear translocation, and synthesis of tissue factor (TF) and tumor necrosis factor alpha (TNF-alpha) in human monocytes. Thromb Haemost1996; 76:970\u2013976.","DOI":"10.1055\/s-0038-1650694"},{"key":"2019111712043741000_B42","doi-asserted-by":"crossref","unstructured":"Matetzky S, Tani S, Kangavari S, et al. Smoking increases tissue factor expression in atherosclerotic plaques: implications for thrombogenicity. Circulation2000; 102:602\u2013604.","DOI":"10.1161\/01.CIR.102.6.602"},{"key":"2019111712043741000_B43","doi-asserted-by":"crossref","unstructured":"Szczeklik A, Musial J, Undas A, et al. Inhibition of thrombin generation by aspirin is blunted in hypercholesterolemia. Arterioscler Thromb Vasc Biol1996; 16:948\u2013954.","DOI":"10.1161\/01.ATV.16.8.948"},{"key":"2019111712043741000_B44","doi-asserted-by":"crossref","unstructured":"Lorand L. Factor XIII: structure, activation, and interactions with fibrinogen and fibrin. Ann N Y Acad Sci2001; 936:291\u2013311.","DOI":"10.1111\/j.1749-6632.2001.tb03516.x"},{"key":"2019111712043741000_B45","doi-asserted-by":"crossref","unstructured":"Ariens RA, Lai TS, Weisel JW, Greenberg CS, Grant PJ. Role of factor XIII in fibrin clot formation and effects of genetic polymorphisms. Blood2002; 100:743\u201354.","DOI":"10.1182\/blood.V100.3.743"},{"key":"2019111712043741000_B46","doi-asserted-by":"crossref","unstructured":"Arie\u0308ns RA, Philipou H, Nagaswani C, Weisel JW, Lane DA, Grant PJ. The factor XIII V34L polymorphism accelerates thrombin activation of FXIII and affects cross-linked fibrin structure. Blood2000; 96:988\u2013936.","DOI":"10.1182\/blood.V96.3.988.015k57_988_995"},{"key":"2019111712043741000_B47","unstructured":"Brozek J, Undas A, Szczeklik A. Aspirin modifies the effect of factor XIII Val34Leu polymorphism on fibrin structure. Paper presented at XVIIth International Congress on Fibrinolysis and Proteolysis 2004 Abstract A557."},{"key":"2019111712043741000_B48","unstructured":"Bjo\u0308rnsson TD, Schneider DE, Berger H Jr. Aspirin acetylates fibrinogen and enhances fibrinolysis: fibrinolytic effect is independent of changes in plasminogen activator levels. J Pharmacol Exp Ther1989; 250:154\u2013161."},{"key":"2019111712043741000_B49","doi-asserted-by":"crossref","unstructured":"Weiss ET, Bray PF, Tayback M, et al. A polymorphism of platelet glycoprotein receptor as an inhibited risk factor for coronary thrombosis. N Engl J Med1996; 334:1090\u20131094.","DOI":"10.1056\/NEJM199604253341703"},{"key":"2019111712043741000_B50","doi-asserted-by":"crossref","unstructured":"Zhu MM, Weddon J, Clark LT. Meta-analysis of the association of platelet glycoprotein IIIa PlA1\/A2 polymorphism with myocardial infarction. Am J Cardiol2000; 86:1000\u20131005.","DOI":"10.1016\/S0002-9149(00)01136-X"},{"key":"2019111712043741000_B51","doi-asserted-by":"crossref","unstructured":"Feng D, Lindpaintner K, Larson MG, et al. Increased platelet aggregability associated with platelet GPIIIa PlA2 polymorphism: the Framingham Offspring Study. Arterioscler Thromb Vasc Biol1999; 19:1142\u20131147.","DOI":"10.1161\/01.ATV.19.4.1142"},{"key":"2019111712043741000_B52","doi-asserted-by":"crossref","unstructured":"Lasne D, Krenn M, Pingault V, et al. Interdonor variability of platelet response to thrombin receptor activation: influence of PlA2 polymorphism. Br J Haematol1997; 99:801\u2013807.","DOI":"10.1046\/j.1365-2141.1997.4973300.x"},{"key":"2019111712043741000_B53","doi-asserted-by":"crossref","unstructured":"Michelson AD, Furman MI, Goldschmidt-Clermont P, et al. Platelet GPIIIa Pl(A) polymorphisms display different sensitivities to aspirin. Circulation2000; 101:1013\u20131018.","DOI":"10.1161\/01.CIR.101.9.1013"},{"key":"2019111712043741000_B54","doi-asserted-by":"crossref","unstructured":"Cooke GE, Bray PF, Hamlington JD, et al. PlA1 polymorphism and efficacy of aspirin. Lancet1998; 351:1253.","DOI":"10.1016\/S0140-6736(05)79320-X"},{"key":"2019111712043741000_B55","doi-asserted-by":"crossref","unstructured":"Undas A, Sanak M, Musial J, Szczeklik A. Platelet glycoprotein IIIa polymorphism, aspirin, and thrombin generation. Lancet1999; 353:982\u2013983.","DOI":"10.1016\/S0140-6736(98)05054-5"},{"key":"2019111712043741000_B56","doi-asserted-by":"crossref","unstructured":"Szczeklik A, Undas A, Sanak M, et al. Relationship between bleeding time, aspirin, and the PlA1\/A2 of platelet glycoprotein IIIa. Br J Haematol2000; 110:965\u2013967.","DOI":"10.1046\/j.1365-2141.2000.02267.x"},{"key":"2019111712043741000_B57","doi-asserted-by":"crossref","unstructured":"Dominguez-Jimenez C, Diaz-Gonzalez E, Gonzalez-Alvaro I, Cesar JM, Sanchez-Madrid E. Prevention of \u03b1IIb\u03b23 activation by non-steroidal anti-inflammatory drugs. FEBS Lett1999; 446:318\u2013322.","DOI":"10.1016\/S0014-5793(99)00236-7"},{"key":"2019111712043741000_B58","doi-asserted-by":"crossref","unstructured":"Schneider DJ, Baumann PQ, Holmes MB, et al. Time and dose dependent augmentation of inhibitory effects of abciximab by aspirin. Thromb Haemost2001; 85:309\u2013313.","DOI":"10.1055\/s-0037-1615685"},{"key":"2019111712043741000_B59","doi-asserted-by":"crossref","unstructured":"Villanueva GV and Allen N. Acetylation of antithrombin III by aspirin. Semin Thromb Haemost1986; 12:213\u2013215.","DOI":"10.1055\/s-2007-1003553"},{"key":"2019111712043741000_B60","doi-asserted-by":"crossref","unstructured":"Mosesson MW, Siebenlist KR, Meh DA. The structure and biological features of fibrinogen and fibrin. Ann N Y Acad Sci2001; 936:11\u201330.","DOI":"10.1111\/j.1749-6632.2001.tb03491.x"},{"key":"2019111712043741000_B61","doi-asserted-by":"crossref","unstructured":"Pinckard RN, Hawkins D, Farr RS. In vitro acetylation of plasma proteins, enzymes and DNA by aspirin. Nature1968; 219:68\u201369.","DOI":"10.1038\/219068a0"},{"key":"2019111712043741000_B62","doi-asserted-by":"crossref","unstructured":"Henschen-Edman AH. Fibrinogen non-inherited heterogeneity and its relationship to function in health and disease. Ann N Y Acad Sci2001; 936:580\u2013593.","DOI":"10.1111\/j.1749-6632.2001.tb03546.x"},{"key":"2019111712043741000_B63","doi-asserted-by":"crossref","unstructured":"Fatah K, Beving H, Albage A, Ivert T, Blo\u0308mback M. Acetylsalicylic acid may protect the patient by increasing fibrin gel porosity. Is withdrawing of treatment harmful to the patient? Eur Heart J1996; 17:1362\u20131366.","DOI":"10.1093\/oxfordjournals.eurheartj.a015070"},{"key":"2019111712043741000_B64","doi-asserted-by":"crossref","unstructured":"Williams S, Fatah K, Hjemdahl P, Blomback M. Better increase in fibrin gel porosity by low-dose than intermediate dose acetylsalicylic acid. Eur Heart J1998; 19:1666\u20131672.","DOI":"10.1053\/euhj.1998.1088"},{"key":"2019111712043741000_B65","doi-asserted-by":"crossref","unstructured":"He S, Blo\u0308mback M, Yoo G, Sinha R, Henschen-Edman AAH. Modified clotting properties of fibrinogen in the presence of acetylsalicylic acid in a purified system. Ann N Y Acad Sci2001; 936:531\u2013535.","DOI":"10.1111\/j.1749-6632.2001.tb03540.x"},{"key":"2019111712043741000_B66","doi-asserted-by":"crossref","unstructured":"Levin RI, Harpel PC, Harpel JG, Recht RA. Inhibition of tissue plasminogen activator by aspirin in vivo and its relationship to level of tPA activator, plasminogen activator and their complexes. Blood1989; 74:1635\u20131643.","DOI":"10.1182\/blood.V74.5.1635.bloodjournal7451635"},{"issue":"2 pt 2","key":"2019111712043741000_B67","first-page":"H429","volume":"266","year":"1994","journal-title":"Am J Physiol"},{"key":"2019111712043741000_B68","doi-asserted-by":"crossref","unstructured":"Hammound HU and Moroz LA. Aspirin and venous occlusion: effects on fibrinolytic activity and tissue-type plasminogen activator. Thromb Res1986; 42:73\u201382.","DOI":"10.1016\/0049-3848(86)90198-2"},{"key":"2019111712043741000_B69","doi-asserted-by":"crossref","unstructured":"Bounameaux H, Gresele P, Hanss M, De Cock F, Vermylen J, Collen D. Aspirin, indomethacin and dazoxiben do not affect the fibrinolytic activation induced by venous occlusion. Thromb Res1985; 40:161\u2013170.","DOI":"10.1016\/0049-3848(85)90326-3"},{"key":"2019111712043741000_B70","doi-asserted-by":"crossref","unstructured":"Geppert A, Graf S, Beckmann R, et al. Concentration of endogenous tPA activator in coronary artery disease: relation to thrombotic events, aspirin treatment, hyperlipidemia, and multivessel disease. Arterioscler Thromb Vasc Biol1998; 18:1634\u20131642.","DOI":"10.1161\/01.ATV.18.10.1634"},{"key":"2019111712043741000_B71","doi-asserted-by":"crossref","unstructured":"Milwidsky A, Finci-Yeleskal Z, Mayer M. Stimulation of plasmin activity by aspirin. Thromb Haemost1991; 65:389\u2013393.","DOI":"10.1055\/s-0038-1648158"},{"key":"2019111712043741000_B72","doi-asserted-by":"crossref","unstructured":"Watala C and Gwozdzinski K. Effect of aspirin on conformation and dynamics of membrane proteins in platelets and erythrocytes. Biochem Pharmacol1993; 45:1343\u20131349.","DOI":"10.1016\/0006-2952(93)90288-8"},{"key":"2019111712043741000_B73","doi-asserted-by":"crossref","unstructured":"Hasan M, Jackson SK, Sinclair AJ. Aspirin-induced conformational changes in platelet membrane in subjects with stroke. Gerontology1995; 41:212\u2013219.","DOI":"10.1159\/000213684"},{"key":"2019111712043741000_B74","doi-asserted-by":"crossref","unstructured":"Winocour PD, Watala C, Perry DW, Kinlough-Rathbone RL. Decreased platelet membrane fluidity due to glycation or acetylation of membrane proteins. Thromb Haemost1992; 68:577\u2013582.","DOI":"10.1055\/s-0038-1646320"},{"key":"2019111712043741000_B75","doi-asserted-by":"crossref","unstructured":"Loew D and Vinazzer H. Dose-dependent influence of acetylsalicylic acid on platelet functions and plasmatic coagulation factors. Haemostasis1976; 5:239\u2013249.","DOI":"10.1159\/000214139"},{"key":"2019111712043741000_B76","doi-asserted-by":"crossref","unstructured":"Ragni M, Golino P, Cirillo P, et al. Endogenous tissue factor pathway inhibitor modulates thrombus formation in an in vivo model of rabbit carotid artery stenosis and endothelial injury. Circulation2000; 102:113\u2013117.","DOI":"10.1161\/01.CIR.102.1.113"},{"key":"2019111712043741000_B77","doi-asserted-by":"crossref","unstructured":"Campbell CL and Steinhubl SR. Variability in response to aspirin: do we understand the clinical relevance? J Thromb Haemost2005; 3:665\u2013669.","DOI":"10.1111\/j.1538-7836.2005.01119.x"},{"key":"2019111712043741000_B78","doi-asserted-by":"crossref","unstructured":"Mason PJ, Jacobs AK, Freedman JE. Aspirin resistance and atherothrombotic disease. J Am Coll Cardiol2005; 46:986\u2013993.","DOI":"10.1016\/j.jacc.2004.08.070"},{"key":"2019111712043741000_B79","doi-asserted-by":"crossref","unstructured":"Sanderson S, Emery J, Baglin T, Kinmonth AL. Narrative review: aspirin resistance and its clinical implications. Ann Intern Med2005; 142:370\u2013380.","DOI":"10.7326\/0003-4819-142-5-200503010-00012"},{"key":"2019111712043741000_B80","doi-asserted-by":"crossref","unstructured":"Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol2003; 41:961\u2013965.","DOI":"10.1016\/S0735-1097(02)03014-0"},{"key":"2019111712043741000_B81","doi-asserted-by":"crossref","unstructured":"Andersen K, Hurlen M, Arnesen H, Seljeflot I. Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res2002; 108:37\u201342.","DOI":"10.1016\/S0049-3848(02)00405-X"},{"key":"2019111712043741000_B82","doi-asserted-by":"crossref","unstructured":"Chen WH, Lee PY, Ng W, Tse HF, Lau CP. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol2004; 43:1122\u20131126.","DOI":"10.1016\/j.jacc.2003.12.034"},{"key":"2019111712043741000_B83","doi-asserted-by":"crossref","unstructured":"Grotemeyer K-H, Scharafinski HW, Husstedt IW. Two-year follow-up of aspirin responder and aspirin non-responder. A pilot study including 180 post-stroke patients. Thromb Res1993; 71:397\u2013403.","DOI":"10.1016\/0049-3848(93)90164-J"},{"key":"2019111712043741000_B84","doi-asserted-by":"crossref","unstructured":"Grundmann K, Jaschonek K, Kleine B, Dichgans J, Topka H. Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J Neurol2003; 250:63\u201366.","DOI":"10.1007\/s00415-003-0954-y"},{"key":"2019111712043741000_B85","doi-asserted-by":"crossref","unstructured":"Schwartz KA, Schwartz DE, Ghosheh K, Reeves MJ, Barber K, DeFranco A. Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction. Am J Cardiol2005; 95:973\u2013975.","DOI":"10.1016\/j.amjcard.2004.12.038"},{"key":"2019111712043741000_B86","doi-asserted-by":"crossref","unstructured":"Catella-Lawson F, Reilly Kapoor SC, Cuchiara AJ, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med2001; 345:1809\u20131817.","DOI":"10.1056\/NEJMoa003199"},{"key":"2019111712043741000_B87","doi-asserted-by":"crossref","unstructured":"MacDonald TM and Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet2003; 361:573\u2013574.","DOI":"10.1016\/S0140-6736(03)12509-3"},{"key":"2019111712043741000_B88","doi-asserted-by":"crossref","unstructured":"Kurth T, Glynn RJ, Walker AM, et al. Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. Circulation2003; 108:1191\u20131195.","DOI":"10.1161\/01.CIR.0000087593.07533.9B"},{"key":"2019111712043741000_B89","doi-asserted-by":"crossref","unstructured":"Hung J, Lam JY, Lacoste L, Letchacovski G. Cigarette smoking acutely increases platelet thrombus formation in patients with coronary artery disease taking aspirin. Circulation1995; 92:2432\u20132436.","DOI":"10.1161\/01.CIR.92.9.2432"},{"key":"2019111712043741000_B90","doi-asserted-by":"crossref","unstructured":"Rocca B, Secchiero P, Ciabattoni G, et al. Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci U S A2002; 99:7634\u20137639.","DOI":"10.1073\/pnas.112202999"},{"key":"2019111712043741000_B91","doi-asserted-by":"crossref","unstructured":"Cippolone F, Rocca B, Patrono C. Cyclooxygenase-2 expression and inhibition in atherosclerosis. Arteriocler Thromb Vasc Biol2004; 24:246\u2013255.","DOI":"10.1161\/01.ATV.0000104005.92603.f2"},{"key":"2019111712043741000_B92","doi-asserted-by":"crossref","unstructured":"Cippolone F, Ciabattoni G, Patrigniani P, et al. Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina. Circulation2000; 102:1007\u20131013.","DOI":"10.1161\/01.CIR.102.9.1007"},{"key":"2019111712043741000_B93","doi-asserted-by":"crossref","unstructured":"Schror K, Weber AA, Hohlfeld T. Aspirin \u201cresistance.\u201d Blood Cells Mol Dis2006; 36:171\u2013176.","DOI":"10.1016\/j.bcmd.2005.12.017"},{"key":"2019111712043741000_B94","doi-asserted-by":"crossref","unstructured":"Cambria-Kiely JA and Gandhi PJ. Aspirin resistance and genetic polymorphisms. J Thromb Thrombolysis2002; 14:51\u201358.","DOI":"10.1023\/A:1022066305399"},{"key":"2019111712043741000_B95","doi-asserted-by":"crossref","unstructured":"Halusha MK, Walker LP, Halushka PV. Genetic variation in cyclooxygenase 1: effects on response to aspirin. Clin Pharmacol Ther2003; 73:122\u2013130.","DOI":"10.1067\/mcp.2003.1"},{"key":"2019111712043741000_B96","doi-asserted-by":"crossref","unstructured":"Gonzalez-Conejero R, Rivera J, Corral J, Acuna C, Guerrero JA, Vicente V. Biological assessment of aspirin efficacy on healthy individuals: heterogenous response or aspirin failure? Stroke2005; 36:276\u2013280.","DOI":"10.1161\/01.STR.0000151362.65339.f9"},{"key":"2019111712043741000_B97","doi-asserted-by":"crossref","unstructured":"Maree AO, Curtin RJ, Chubb A, et al. Cyclooxygenase-1 haplotype modulates platelet response to aspirin. J Thromb Haemost2005; 3:2340\u20132345.","DOI":"10.1111\/j.1538-7836.2005.01555.x"},{"key":"2019111712043741000_B98","doi-asserted-by":"crossref","unstructured":"Jefferson BK, Foster JH, McCarthy JJ, et al. Aspirin resistance and a single gene. Am J Cardiol2005; 95:805\u2013808.","DOI":"10.1016\/j.amjcard.2004.11.045"},{"key":"2019111712043741000_B99","doi-asserted-by":"crossref","unstructured":"Helgason CM, Bolin KM, Hoff JA, et al. Development of aspirin resistance in persons with previous ischemic stroke. Stroke1994; 25:2331\u20132336.","DOI":"10.1161\/01.STR.25.12.2331"},{"key":"2019111712043741000_B100","doi-asserted-by":"crossref","unstructured":"Pulcinelli FM, Pignatelli P, Celestini A, Riondino S, Gazzaniga PP, Violi F. Inhibition of platelet aggregation by aspirin progressively decreases in long-term-treated patients. J Am Coll Cardiol2004; 43:979\u2013984.","DOI":"10.1016\/j.jacc.2003.08.062"},{"key":"2019111712043741000_B101","doi-asserted-by":"crossref","unstructured":"DeGaetano G and Cerletti C. Aspirin resistance: a revival of aspirin aggregation tests? J Thromb Haemost2003; 1:1710\u20131713.","DOI":"10.1046\/j.1538-7836.2003.00354.x"},{"key":"2019111712043741000_B102","doi-asserted-by":"crossref","unstructured":"Michelson AD, Cattaneo M, Eikelboom JW, et al. Aspirin resistance: position paper of the Working Group of Aspirin Resistance. J Thromb Haemost2005; 3:1309\u20131311.","DOI":"10.1111\/j.1538-7836.2005.01351.x"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/109\/6\/2285\/1477666\/zh800607002285.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/109\/6\/2285\/1477666\/zh800607002285.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T13:29:00Z","timestamp":1628170140000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/109\/6\/2285\/23279\/Antithrombotic-properties-of-aspirin-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,12,5]]},"references-count":102,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2006,12,5]]},"published-print":{"date-parts":[[2007,3,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2006-01-010645","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,12,5]]}}}